Search results

3873 results

Sorted by Relevance . Sort by Date

  1. Liver cancers

    Everything NICE has said on liver and bile duct cancers in an interactive flowchart

  2. Alcohol-use disorders

    Everything NICE has said on preventing, diagnosing and managing alcohol-related disorders in an interactive flowchart

  3. Neonatal jaundice

    Everything NICE has said on diagnosing and treating jaundice in newborn babies under 28 days in an interactive flowchart

  4. Headaches

    Everything NICE has said on the most common primary headache disorders in young people aged 12 years and older and adults in an interactive flowchart

  5. Type 1 diabetes in adults

    Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart

  6. Chronic kidney disease

    Everything NICE has said on chronic kidney disease (renal failure) in an interactive flowchart

  7. Hypertension

    Everything NICE has said on managing hypertension in adults in an interactive flowchart

  8. Diabetes in children and young people

    Everything NICE has said on diagnosing and managing type 1 and 2 diabetes in children and young people in an interactive flowchart

  9. Multiple sclerosis

    Everything NICE has said on multiple sclerosis in an interactive flowchart

  10. Psychosis and schizophrenia

    Everything NICE has said on recognising and managing psychosis and schizophrenia in children, young people and adults in an interactive flowchart

  11. Low back pain and sciatica

    Everything NICE has said on low back pain and sciatica in an interactive flowchart

  12. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  13. Parkinson's disease

    Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

  14. Neuropathic pain

    Everything NICE has said on pharmacological management of neuropathic pain in adults in non-specialist settings in an interactive flowchart

  15. Suspected cancer recognition and referral

    Everything NICE has said on suspected cancer, recognition and selection for referral or investigation in primary care in an interactive flowchart

  16. Skin conditions

    Everything NICE has said on managing skin conditions and skin damage in an interactive flowchart

  17. Epilepsy

    Everything NICE has said on diagnosing and managing the epilepsies in adults and children in primary and secondary care in an interactive flowchart

  18. Lung cancer

    Everything NICE has said on diagnosing and treating lung cancer in an interactive flowchart

  19. Contraception

    Everything NICE has said on contraceptive services, long-acting reversible contraception and sterilisation in an interactive flowchart

  20. Lower limb peripheral arterial disease

    Everything NICE has said on diagnosing and managing lower limb peripheral arterial disease in an interactive flowchart

  21. Antimicrobial stewardship

    Everything NICE has said on effective antimicrobial medicine use and preventing the spread of resistant microbes in an interactive flowchart

  22. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  23. Neurological conditions

    Everything NICE has said on neurological conditions in an interactive flowchart

  24. Chest pain

    Everything NICE has said on assessing and managing recent suspected cardiac chest pain including acute coronary syndromes and stable angina in an interactive flowchart

  25. Renal cancer

    Everything NICE has said on renal (kidney) cancer in an interactive flowchart

  26. Constipation

    Everything NICE has said on constipation in an interactive flowchart

  27. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.

  28. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  29. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  30. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  31. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  32. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  33. COVID-19 rapid guideline: cystic fibrosis (NG170)

    The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.

  34. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  35. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .

  36. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

  37. COVID-19 rapid guideline: acute myocardial injury (NG171)

    The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease.

  38. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    The purpose of this guideline is to help healthcare professionals prevent, detect and manage acute kidney injury in adults in hospital with known or suspected COVID-19. This is important to improve outcomes and reduce the need for renal replacement therapy.

  39. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  40. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  41. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

  42. COVID-19 rapid guideline: severe asthma (NG166)

    The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  43. COVID-19 rapid guideline: critical care in adults (NG159)

    The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.